• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Within the Herpes and Respiratory Antiviral Subcategory HSV/VZV Products Have Been Key Growth Drivers, Accounting for 77% of a Market Worth $2,190m in 2004

Posted on: Monday, 21 November 2005, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c28097) has announced the addition of Herpes and Respiratory Antivirals - Leaders Rise and Fall to their offering.

Within the herpes and respiratory antiviral subcategory HSV/VZV products have been key growth drivers, accounting for 77% of a market worth $2,190m in 2004. Despite lost of US branded Valtrex in 2009, the continued uptake of flu and post-transplant CMV antivirals along with the anticipated launch of first-in-class RSV antiviral, A-60444 will to some extent offset revenue loss by 2014.

The anti-infective vaccine market is poised for explosive growth, leading to a shift of R&D focus from antiviral therapy to preventative vaccination and hence a dwindling herpes and respiratory antiviral pipeline. However, clinical unmet needs mainly in CMV, VZV related post-herpetic neuralgia (PHN) and RSV maintain the call for new products.

Capitalizing on the Zovirax legacy, a large number of indication expansions and effective marketing strategies by ID leader GSK, sales of follow-up product Valtrex have experienced accelerated growth. In 2004, Valtrex achieved blockbuster status, selling $1,090m in the seven major markets.

Currently available RSV therapies are sub-optimal and expensive, being reserved for at risk immunocompromised patient groups such as neonates. With successful development and positioning of first-in-class RSV small molecule inhibitor A-60444, Arrow/Novartis could establish a new treatment paradigm in RSV.

Scope of the report:

- Market overview by geographical area and disease indication, with value analysis of clinical and commercial factors underlying product performance

- Assessment of country-specific drivers and resistors likely to impact the herpes and respiratory antiviral market

- Case study analysis of the key players in the market and further the success of follow-up products Valtrex for HSV/VZV and Valcyte for CMV

- Future market outlook per disease indication and individual products taking into account key market events in particular, patent expiries

Reasons to Purchase

- Identify key environmental opportunities and threats that will impact the use and uptake of new and existing products

- Select effective lifecycle management strategies through best-in-class case study analysis of key players in the market

- Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

For more information visit http://www.researchandmarkets.com/reports/c28097

Source: Business Wire

More News in this Category